SeaCrest Wealth Management LLC lowered its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 62.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,369 shares of the company’s stock after selling 5,544 shares during the quarter. SeaCrest Wealth Management LLC’s holdings in CRISPR Therapeutics were worth $282,000 at the end of the most recent reporting period.
Other hedge funds also recently made changes to their positions in the company. Vigilant Capital Management LLC bought a new position in CRISPR Therapeutics during the third quarter worth $25,000. Webster Bank N. A. bought a new stake in CRISPR Therapeutics in the 3rd quarter valued at $27,000. Pacitti Group Inc. bought a new stake in CRISPR Therapeutics in the 2nd quarter valued at $32,000. WASHINGTON TRUST Co increased its holdings in CRISPR Therapeutics by 81.9% in the 2nd quarter. WASHINGTON TRUST Co now owns 473 shares of the company’s stock valued at $35,000 after buying an additional 213 shares during the period. Finally, Nachman Norwood & Parrott Inc bought a new stake in CRISPR Therapeutics in the 3rd quarter valued at $42,000. 55.19% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ CRSP opened at $110.00 on Friday. The firm’s 50-day simple moving average is $100.75 and its 200 day simple moving average is $84.83. The company has a market cap of $7.77 billion, a price-to-earnings ratio of -33.74 and a beta of 2.26. CRISPR Therapeutics AG has a 12-month low of $32.30 and a 12-month high of $111.90.
CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, November 2nd. The company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.14). CRISPR Therapeutics had a negative net margin of 273.10% and a negative return on equity of 20.72%. The business had revenue of $0.15 million for the quarter, compared to analyst estimates of $2.22 million. During the same quarter in the previous year, the company posted $2.40 earnings per share. The business’s revenue for the quarter was down 99.9% on a year-over-year basis. On average, research analysts predict that CRISPR Therapeutics AG will post -4.97 earnings per share for the current year.
In other CRISPR Therapeutics news, President Rodger Novak sold 25,000 shares of the company’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $92.62, for a total transaction of $2,315,500.00. Following the transaction, the president now directly owns 651,940 shares in the company, valued at approximately $60,382,682.80. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Bradley J. Phd Bolzon sold 3,035 shares of the company’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $86.87, for a total transaction of $263,650.45. Following the transaction, the director now owns 7,391 shares in the company, valued at $642,056.17. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 133,000 shares of company stock worth $12,064,743. Corporate insiders own 21.40% of the company’s stock.
CRSP has been the topic of several analyst reports. Citigroup reissued a “sell” rating on shares of CRISPR Therapeutics in a report on Wednesday, August 5th. Stifel Nicolaus boosted their price target on shares of CRISPR Therapeutics from $75.00 to $93.00 and gave the company a “hold” rating in a report on Wednesday, October 21st. Bank of America initiated coverage on shares of CRISPR Therapeutics in a report on Monday, October 5th. They issued a “buy” rating and a $110.00 target price on the stock. Roth Capital upped their target price on shares of CRISPR Therapeutics from $105.00 to $115.00 and gave the stock a “buy” rating in a report on Wednesday, October 21st. Finally, Piper Sandler lowered their target price on shares of CRISPR Therapeutics from $128.00 to $107.00 and set an “overweight” rating on the stock in a report on Thursday, October 29th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and fourteen have issued a buy rating to the company. CRISPR Therapeutics has a consensus rating of “Buy” and a consensus price target of $101.20.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.
Read More: How to calculate compound interest
Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP).
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.